These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21104786)

  • 21. Comparison of the reference scaled bioequivalence semi-replicate method with other approaches: focus on human exposure to drugs.
    Karalis V; Symillides M; Macheras P
    Eur J Pharm Sci; 2009 Aug; 38(1):55-63. PubMed ID: 19524039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Power analyses for correlations from clustered study designs.
    Tu XM; Kowalski J; Crits-Christoph P; Gallop R
    Stat Med; 2006 Aug; 25(15):2587-606. PubMed ID: 16025545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The assessment of non-inferiority in a gold standard design with censored, exponentially distributed endpoints.
    Mielke M; Munk A; Schacht A
    Stat Med; 2008 Nov; 27(25):5093-110. PubMed ID: 18570271
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A two-stage sample size recalculation procedure for placebo- and active-controlled non-inferiority trials.
    Schwartz TA; Denne JS
    Stat Med; 2006 Oct; 25(19):3396-406. PubMed ID: 16900573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Choice of designs and doses for early phase trials.
    Zhou Y
    Fundam Clin Pharmacol; 2004 Jun; 18(3):373-8. PubMed ID: 15147290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tests for inter-subject and total variabilities under crossover designs.
    Lee Y; Shao J; Chow SC; Wang H
    J Biopharm Stat; 2002 Nov; 12(4):503-34. PubMed ID: 12477072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sample-size calculations for studies with correlated ordinal outcomes.
    Kim HY; Williamson JM; Lyles CM
    Stat Med; 2005 Oct; 24(19):2977-87. PubMed ID: 16149125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of performance of some enrichment designs dealing with high placebo response in psychiatric clinical trials.
    Chen YF; Yang Y; Hung HM; Wang SJ
    Contemp Clin Trials; 2011 Jul; 32(4):592-604. PubMed ID: 21540126
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sample size determination for assessing equivalence based on proportion ratio under a randomized trial with non-compliance and missing outcomes.
    Lui KJ; Chang KC
    Stat Med; 2008 Jan; 27(1):47-67. PubMed ID: 17708514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal design of clinical trials comparing several treatments with a control.
    Marschner IC
    Pharm Stat; 2007; 6(1):23-33. PubMed ID: 17323312
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tests for equivalence based on odds ratio for matched-pair design.
    Liu JP; Fan HY; Ma MC
    J Biopharm Stat; 2005; 15(6):889-901. PubMed ID: 16279349
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Study design and simulation approach.
    Läer S; Meibohm B
    Handb Exp Pharmacol; 2011; 205():125-48. PubMed ID: 21882109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and analysis of non-inferiority mortality trials in oncology.
    Carroll K; Milsted B; Lewis JA
    Stat Med; 2004 Sep; 23(17):2771-4; author reply 2774-8. PubMed ID: 15316946
    [No Abstract]   [Full Text] [Related]  

  • 34. In vitro bioequivalence testing.
    Chow SC; Shao J; Wang H
    Stat Med; 2003 Jan; 22(1):55-68. PubMed ID: 12486751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sample size calculations for population pharmacodynamic experiments involving repeated dichotomous observations.
    Ogungbenro K; Aarons L
    J Biopharm Stat; 2008; 18(6):1212-27. PubMed ID: 18991118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Determining the error of dose estimates and minimum and maximum acceptable concentrations from assays with nonlinear dose-response curves.
    Gottschalk PG; Dunn JR
    Comput Methods Programs Biomed; 2005 Dec; 80(3):204-15. PubMed ID: 16256244
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The challenges of evaluating dose response in flexible-dose trials using marginal structural models.
    Lipkovich I; Mallinckrodt CH; Faries DE
    Pharm Stat; 2012; 11(6):485-93. PubMed ID: 23060290
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inference methods for saturated models in longitudinal clinical trials with incomplete binary data.
    Song JX
    Pharm Stat; 2006; 5(4):295-304. PubMed ID: 17128429
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Noninferiority testing beyond simple two-sample comparison.
    Tsong Y; Chen WJ
    J Biopharm Stat; 2007; 17(2):289-308. PubMed ID: 17365225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design of the "Thorough QT Study".
    Darpo B; Sager P
    Clin Pharmacol Ther; 2008 Apr; 83(4):529; author reply 530. PubMed ID: 18043696
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.